319 related articles for article (PubMed ID: 24479803)
1. Targeting miRNAs for pancreatic cancer therapy.
Shi M; Xie D; Gaod Y; Xie K
Curr Pharm Des; 2014; 20(33):5279-86. PubMed ID: 24479803
[TBL] [Abstract][Full Text] [Related]
2. Signaling of miRNAs-FOXM1 in cancer and potential targeted therapy.
Shi M; Cui J; Xie K
Curr Drug Targets; 2013 Sep; 14(10):1192-202. PubMed ID: 23834153
[TBL] [Abstract][Full Text] [Related]
3. FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis.
Huang C; Du J; Xie K
Biochim Biophys Acta; 2014 Apr; 1845(2):104-16. PubMed ID: 24418574
[TBL] [Abstract][Full Text] [Related]
4. FOXM1-induced miR-552 expression contributes to pancreatic cancer progression by targeting multiple tumor suppressor genes.
Wang X; Dou N; Wang J; Zhang Y; Li Y; Gao Y
Int J Biol Sci; 2021; 17(4):915-925. PubMed ID: 33867818
[TBL] [Abstract][Full Text] [Related]
5. Developments in miRNA gene signaling pathways in pancreatic cancer.
Vorvis C; Koutsioumpa M; Iliopoulos D
Future Oncol; 2016 May; 12(9):1135-50. PubMed ID: 26984178
[TBL] [Abstract][Full Text] [Related]
6. FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression.
Cui J; Shi M; Xie D; Wei D; Jia Z; Zheng S; Gao Y; Huang S; Xie K
Clin Cancer Res; 2014 May; 20(10):2595-606. PubMed ID: 24634381
[TBL] [Abstract][Full Text] [Related]
7. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system.
Huang C; Xie D; Cui J; Li Q; Gao Y; Xie K
Clin Cancer Res; 2014 Mar; 20(6):1477-88. PubMed ID: 24452790
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of key microRNAs in pancreatic cancer development.
Baradaran B; Shahbazi R; Khordadmehr M
Biomed Pharmacother; 2019 Jan; 109():1008-1015. PubMed ID: 30551350
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.
Rachagani S; Macha MA; Heimann N; Seshacharyulu P; Haridas D; Chugh S; Batra SK
Adv Drug Deliv Rev; 2015 Jan; 81():16-33. PubMed ID: 25453266
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.
Xia JT; Wang H; Liang LJ; Peng BG; Wu ZF; Chen LZ; Xue L; Li Z; Li W
Pancreas; 2012 May; 41(4):629-35. PubMed ID: 22249132
[TBL] [Abstract][Full Text] [Related]
11. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer.
Kong X; Li L; Li Z; Le X; Huang C; Jia Z; Cui J; Huang S; Wang L; Xie K
Cancer Res; 2013 Jul; 73(13):3987-96. PubMed ID: 23598278
[TBL] [Abstract][Full Text] [Related]
12. A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis.
Huang C; Qiu Z; Wang L; Peng Z; Jia Z; Logsdon CD; Le X; Wei D; Huang S; Xie K
Cancer Res; 2012 Feb; 72(3):655-65. PubMed ID: 22194465
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs as biomarkers and perspectives in the therapy of pancreatic cancer.
Xia T; Chen XY; Zhang YN
Mol Cell Biochem; 2021 Dec; 476(12):4191-4203. PubMed ID: 34324119
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells.
Bao B; Wang Z; Ali S; Kong D; Banerjee S; Ahmad A; Li Y; Azmi AS; Miele L; Sarkar FH
J Cell Biochem; 2011 Sep; 112(9):2296-306. PubMed ID: 21503965
[TBL] [Abstract][Full Text] [Related]
15. Prospects of miRNA-based therapy for pancreatic cancer.
Pai P; Rachagani S; Are C; Batra SK
Curr Drug Targets; 2013 Sep; 14(10):1101-9. PubMed ID: 23834151
[TBL] [Abstract][Full Text] [Related]
16. Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy.
Khan MA; Zubair H; Srivastava SK; Singh S; Singh AP
Adv Exp Med Biol; 2015; 889():71-87. PubMed ID: 26658997
[TBL] [Abstract][Full Text] [Related]
17. Investigating the regulatory role of miRNAs as silent conductors in the management of pathogenesis and therapeutic resistance of pancreatic cancer.
Abulsoud AI; Elshaer SS; Abdelmaksoud NM; Zaki MB; El-Mahdy HA; Ismail A; Al-Noshokaty TM; Fathi D; Abdel-Reheim MA; Mohammed OA; Doghish AS
Pathol Res Pract; 2023 Nov; 251():154855. PubMed ID: 37806169
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of circular RNAs and autophagy-related miRNAs in the diagnosis and treatment of pancreatic cancer.
Jiang PC; Bu SR
Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):511-516. PubMed ID: 31610988
[TBL] [Abstract][Full Text] [Related]
20. Mir-320b Inhibits Pancreatic Cancer Cell Proliferation by Targeting FOXM1.
Jingyang Z; Jinhui C; Lu X; Weizhong Y; Yunjiu L; Haihong W; Wuyuan Z
Curr Pharm Biotechnol; 2021; 22(8):1106-1113. PubMed ID: 32942974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
